Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ophthalmic Epidemiol ; 23(4): 232-7, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27340738

RESUMO

PURPOSE: To estimate the prevalence of wet age-related macular degeneration (AMD) in Singapore in the year 2030. This projection will help in planning appropriate care provision and build health services capacity to cater to the increasing healthcare demand in 2030. METHODS: The number of AMD patients aged 40-79 years from all Singaporeans was estimated using prevalence rates from a local study and using the United Nations population projections for Singapore to 2030. Age-specific mortality was accounted for. Additionally, two main scenarios were presented: (1) Projected number of wet AMD cases if patients were not taking preventive antioxidant vitamins; (2) projected number of wet AMD cases if patients were taking preventive antioxidant vitamins. Based on these scenarios, the economic burden was calculated. The number of quality-adjusted life years (QALYs) gained as a result of improvement in visual acuity (VA) due to anti-vascular endothelial growth factor (VEGF) treatment was also calculated. RESULTS: An estimated growth of 42% in the number of wet AMD cases is expected by 2030. The estimated economic burden of wet AMD in 2030 for scenarios 1 and 2 is Singapore $203.1 million and $162.9 million, respectively. The QALYs gained as a result of improved VA from wet AMD treatment ranged from 10,114.4 to 14,058.8 over a 5-year period for the 2030 cohort. CONCLUSION: The burden of wet AMD is set to increase over the next 15 years. Appropriate measures to build healthcare capacity and plan for this expected surge in patients should be a priority in Singapore.


Assuntos
Degeneração Macular Exsudativa/economia , Degeneração Macular Exsudativa/epidemiologia , Adulto , Idoso , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Método de Monte Carlo , Prevalência , Anos de Vida Ajustados por Qualidade de Vida , Singapura/epidemiologia , Fatores de Crescimento do Endotélio Vascular/uso terapêutico , Acuidade Visual , Degeneração Macular Exsudativa/tratamento farmacológico
2.
Retina ; 33(4): 686-716, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23455233

RESUMO

BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy affecting vision, with clinical features distinct from neovascular age-related macular degeneration. Currently, no evidence-based guidelines exist for its diagnosis and treatment. METHODS: A panel of experts analyzed a systematic literature search on PCV together with results of the EVEREST trial, the only published randomized controlled clinical trial in PCV. At a subsequent Roundtable meeting, recommendations for the management of PCV were agreed based on this analysis and their own expert opinion. RESULTS: Diagnosis of PCV should be based on early-phase nodular hyperfluorescence from choroidal vasculature visualized using indocyanine green angiography. Recommended initial treatment of juxtafoveal and subfoveal PCV is either indocyanine green angiography-guided verteporfin photodynamic therapy or verteporfin photodynamic therapy plus 3 × 0.5 mg ranibizumab intravitreal injections 1 month apart. If there is incomplete regression of polyps by indocyanine green angiography, eyes should be retreated with verteporfin photodynamic therapy monotherapy or verteporfin photodynamic therapy plus ranibizumab. If there is complete regression of polyps by indocyanine green angiography, but there is leakage on fluorescein angiography and other clinical or anatomical signs of disease activity, eyes should be retreated with ranibizumab. CONCLUSION: Practical guidance on the clinical management of PCV is proposed based on expert evaluation of current evidence.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Doenças da Coroide/diagnóstico , Doenças da Coroide/tratamento farmacológico , Corioide/irrigação sanguínea , Corantes , Fotoquimioterapia , Pólipos/diagnóstico , Pólipos/tratamento farmacológico , Anticorpos Monoclonais Humanizados/uso terapêutico , Bases de Dados Factuais , Medicina Baseada em Evidências , Angiofluoresceinografia , Humanos , Verde de Indocianina , Fármacos Fotossensibilizantes/uso terapêutico , Porfirinas/uso terapêutico , Ranibizumab , Verteporfina
3.
Telemed J E Health ; 14(8): 833-45, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18954255

RESUMO

This paper describes a secure and synthesis ophthalmology telemedicine system, referred to as TeleOph. Under a Secure Socket Layer (SSL) channel, patient prerecorded data can be safely transferred via the Internet. With encrypted videoconference and white-board, the system not only supports hospital-to-clinic consultation, but also supplies hospital-tohospital joint discussion. Based on Directshow technology (Microsoft Corporation, Redmond, WA), video cameras connected to the computer by firewire can be captured and controlled to sample video data. By using TWAIN technology, the system automatically identifies networked still cameras (on fundus and slitlamp devices) and retrieves images. All the images are stored in a selected format (such as JPEG, DICOM, BMP). Besides offline-transferring prerecorded data, the system also supplies online sampling of patient data (real-time capturing from remote places). The system was deployed at Tan Tock Seng Hospital, Singapore and Ang Mo Kio, Singapore, where 100 patients were enrolled in the system for examination. TeleOph can be successfully used for patient consultation, and hospital joint discussion. Meanwhile, TeleOph can supply both offline and online sampling of patient data.


Assuntos
Oftalmologia/instrumentação , Telemedicina/instrumentação , Comunicação por Videoconferência/instrumentação , Segurança de Equipamentos , Feminino , Humanos , Masculino , Oftalmologia/métodos , Sensibilidade e Especificidade , Design de Software , Taiwan
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...